PL366233A1 - Podstawione pirydoindole jako agoniści i antagoniści serotoniny - Google Patents

Podstawione pirydoindole jako agoniści i antagoniści serotoniny

Info

Publication number
PL366233A1
PL366233A1 PL01366233A PL36623301A PL366233A1 PL 366233 A1 PL366233 A1 PL 366233A1 PL 01366233 A PL01366233 A PL 01366233A PL 36623301 A PL36623301 A PL 36623301A PL 366233 A1 PL366233 A1 PL 366233A1
Authority
PL
Poland
Prior art keywords
antagonists
serotonin agonists
pyridoindoles
substituted
substituted pyridoindoles
Prior art date
Application number
PL01366233A
Other languages
English (en)
Inventor
Albert J. Robichaud
John M. Fevig
Ian S. Mitchell
Taekyu Lee
Wenting Chen
Joseph Cacciola
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of PL366233A1 publication Critical patent/PL366233A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/16—Peri-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL01366233A 2000-12-20 2001-12-19 Podstawione pirydoindole jako agoniści i antagoniści serotoniny PL366233A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25674000P 2000-12-20 2000-12-20

Publications (1)

Publication Number Publication Date
PL366233A1 true PL366233A1 (pl) 2005-01-24

Family

ID=22973405

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01366233A PL366233A1 (pl) 2000-12-20 2001-12-19 Podstawione pirydoindole jako agoniści i antagoniści serotoniny

Country Status (18)

Country Link
US (1) US6699852B2 (pl)
EP (1) EP1343791A2 (pl)
JP (1) JP4231290B2 (pl)
KR (1) KR20030070073A (pl)
BG (1) BG107865A (pl)
BR (1) BR0116429A (pl)
CA (1) CA2432185C (pl)
EE (1) EE200300296A (pl)
HU (1) HUP0303432A3 (pl)
IL (1) IL156354A0 (pl)
IS (1) IS6849A (pl)
MX (1) MXPA03005438A (pl)
NO (1) NO20032797L (pl)
PL (1) PL366233A1 (pl)
RU (1) RU2003121304A (pl)
SK (1) SK7042003A3 (pl)
WO (1) WO2002059129A2 (pl)
ZA (1) ZA200304305B (pl)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858604B2 (en) * 2000-11-03 2005-02-22 Wyeth Cyclohepta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
AR031200A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Cicloocta [b] [1,4] diazepino [6,7,1-hi] indoles y derivados
US6777407B2 (en) * 2000-11-03 2004-08-17 Wyeth Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
TW200307540A (en) * 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307682A (en) * 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
IL166593A0 (en) * 2002-08-02 2006-01-15 Racemization and enantiomer separation of clopidogrel
WO2004056324A2 (en) 2002-12-19 2004-07-08 Bristol-Myers Squibb Company Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
GB0306604D0 (en) * 2003-03-21 2003-04-30 Curidium Ltd Second medical use
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
DK1737461T3 (da) 2004-03-15 2013-03-18 Ptc Therapeutics Inc Carbolin-derivater til inhibering af angiogenese
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
JP5173190B2 (ja) 2004-08-25 2013-03-27 武田薬品工業株式会社 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
PE20060939A1 (es) * 2004-11-05 2006-11-10 Wyeth Corp Metabolitos derivados de [1,4] diazepin[6,7,1-ij] quinolina y procedimiento de preparacion
AR051946A1 (es) * 2004-11-05 2007-02-21 Wyeth Corp Formulaciones de derivados de [1,4] diazepina [6,7,1-ij] quinolina
AT502251B1 (de) * 2005-05-06 2007-12-15 Puchegger U Beisteiner Parkett Fussbodenschleifmaschine
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
WO2007016353A2 (en) * 2005-07-28 2007-02-08 Bristol-Myers Squibb Company Substituted tetrahydro-1h-pyrido[4,3,b]indoles as serotonin receptor agonists and antagonists
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
US20070225274A1 (en) * 2006-03-24 2007-09-27 Wyeth Methods for modulating bladder function
CA2644618A1 (en) * 2006-03-24 2007-10-04 Wyeth Methods for treating cognitive and other disorders
KR20080110759A (ko) * 2006-03-24 2008-12-19 와이어쓰 통증 치료
KR20080105104A (ko) * 2006-03-24 2008-12-03 와이어쓰 우울증 치료를 위한 신규한 치료학적 병용제
JP5528699B2 (ja) 2006-05-16 2014-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
CN103626766B (zh) 2007-03-12 2017-06-09 细胞内治疗公司 与取代的杂环稠合的γ‑咔啉的合成
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
EP2476680B1 (en) 2008-01-11 2014-08-27 Albany Molecular Research, Inc. (1-Azinone)-Substituted Pyridoindoles
US8629158B2 (en) * 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011003005A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
WO2011003021A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
US8367655B2 (en) * 2009-07-03 2013-02-05 Daya Drug Discoveries, Inc. Pyridoindolobenzox—and thiazepine derivatives and uses thereof
US20120253036A1 (en) 2009-12-11 2012-10-04 Yukinori Nagakura Agent for treating fibromyalgia
WO2012030953A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
EP2824106B1 (en) * 2012-03-06 2016-11-23 Takeda Pharmaceutical Company Limited Tricyclic compound
ES2727815T3 (es) 2012-04-14 2019-10-18 Intra Cellular Therapies Inc Tratamiento del TEPT y de trastornos del control de impulsos
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
PL2968320T3 (pl) 2013-03-15 2021-05-17 Intra-Cellular Therapies, Inc. Związki organiczne
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
CA3205777A1 (en) 2013-12-03 2015-06-11 Intra-Cellular Therapies, Inc. Heterocycle fused gamma-carboline compounds for use in treatment of schizophrenia
BR112016023162B1 (pt) 2014-04-04 2022-11-29 Intra-Cellular Therapies, Inc Compostos orgânicos gama-carbolinas, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento ou na profilaxia de transtornos de sistema nervoso central
CA2944755A1 (en) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
WO2017132408A1 (en) 2016-01-26 2017-08-03 Intra-Cellular Therapies, Inc. Organic compounds
KR102483124B1 (ko) 2016-03-25 2022-12-29 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
WO2017172795A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
EP3436016B1 (en) 2016-03-28 2022-04-27 Intra-Cellular Therapies, Inc. Novel co-crystals
US10654854B2 (en) 2016-03-28 2020-05-19 Intra-Cellular Therapies, Inc. Salts and crystals of ITI-007
US11331316B2 (en) 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
WO2018126143A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
MX2019011329A (es) 2017-03-24 2019-12-02 Intra Celular Therapies Inc Composiciones novedosas y metodos.
MX2020000968A (es) 2017-07-26 2020-09-28 Intra Cellular Therapies Inc Compuestos organicos.
KR102667268B1 (ko) 2017-07-26 2024-05-17 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
CN111107847A (zh) 2017-09-26 2020-05-05 细胞内治疗公司 新的盐和晶体
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
EP3765021A4 (en) 2018-03-16 2022-03-09 Intra-Cellular Therapies, Inc. NOVEL PROCESSES
CN110831941A (zh) 2018-06-11 2020-02-21 细胞内治疗公司 取代的杂环稠合的γ-咔啉类化合物合成
WO2020047407A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
JP7457000B2 (ja) 2018-08-31 2024-03-27 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規方法
BR112021016620A2 (pt) 2019-02-27 2021-11-03 Univ California Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais
JP7261942B2 (ja) 2019-12-11 2023-04-20 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3299078A (en) 1962-10-01 1967-01-17 Smith Kline French Lab Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines
US4013652A (en) 1972-06-19 1977-03-22 Endo Laboratories, Inc. Pyridopyrrolobenzoxazine
US3914421A (en) * 1972-06-19 1975-10-21 Endo Lab Pyridopyrrolobenzheterocycles for combatting depression
US4238607A (en) * 1972-06-19 1980-12-09 Endo Laboratories Inc. Pyridopyrrolo benzheterocycles
US4183936A (en) * 1972-06-19 1980-01-15 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US4115577A (en) * 1972-06-19 1978-09-19 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
FR2213283A1 (en) 1973-11-15 1974-08-02 Inst Im Ordzhonikidze Pyrazino(1,2,3-ab)beta carbolines and homologues - antidepressants not acting by MAO inhibition
US4088647A (en) 1976-02-04 1978-05-09 Glushkov Robert Georgievich Pyrazino (1,2,3-ab)-β-carboline derivatives and salts thereof and method of preparing same
US4219550A (en) 1978-11-09 1980-08-26 E. I. Du Pont De Nemours And Company Cis- and trans- octahydropyridopyrrolobenzheterocycles
US5328905A (en) 1987-07-20 1994-07-12 Duphar International Research B.V. 8,9-anellated-1,2,3,4-tetrahydro-β-carboline derivatives
ATE136032T1 (de) 1987-07-20 1996-04-15 Duphar Int Res 8,9-anellierte 1,2,3,4-tetrahydro-beta-carbolin- derivate
JPH02180885A (ja) 1988-09-01 1990-07-13 Glaxo Group Ltd ラクタム誘導体
US5223625A (en) 1988-12-22 1993-06-29 Duphar International Research B.V. Annelated indolo [3,2,-C]lactams
CA2011107A1 (en) 1990-02-28 1991-08-31 David E. Bays Lactam derivatives
WO1995011245A1 (fr) 1993-10-20 1995-04-27 Tokyo Tanabe Company Limited Derive d'indole
US6407092B1 (en) * 1999-04-23 2002-06-18 Pharmacia & Upjohn Company Tetracyclic azepinoindole compounds
AR023574A1 (es) 1999-04-23 2002-09-04 Pharmacia & Upjohn Co Llc Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
CN1371374A (zh) * 1999-06-15 2002-09-25 杜邦药品公司 取代的杂环稠合γ－咔啉

Also Published As

Publication number Publication date
US20020173503A1 (en) 2002-11-21
CA2432185A1 (en) 2002-08-01
CA2432185C (en) 2011-11-08
NO20032797D0 (no) 2003-06-19
RU2003121304A (ru) 2005-01-27
SK7042003A3 (en) 2004-07-07
WO2002059129A2 (en) 2002-08-01
EP1343791A2 (en) 2003-09-17
BG107865A (en) 2004-07-30
EE200300296A (et) 2003-12-15
JP2005506281A (ja) 2005-03-03
HUP0303432A3 (en) 2012-09-28
NO20032797L (no) 2003-08-19
HUP0303432A2 (hu) 2004-01-28
ZA200304305B (en) 2004-09-02
WO2002059129A3 (en) 2003-01-30
IL156354A0 (en) 2004-01-04
KR20030070073A (ko) 2003-08-27
US6699852B2 (en) 2004-03-02
MXPA03005438A (es) 2004-05-05
IS6849A (is) 2003-06-18
BR0116429A (pt) 2006-05-09
JP4231290B2 (ja) 2009-02-25

Similar Documents

Publication Publication Date Title
PL366233A1 (pl) Podstawione pirydoindole jako agoniści i antagoniści serotoniny
IL154604A0 (en) Guanidinobenzamides as mc4-r agonists
IL153181A0 (en) Glucagon antagonists/inverse agonists
IL150898A0 (en) Novel melanocortin receptor agonists and antagonists
HUP0303530A3 (en) Stituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists and pharmaceutical compositions containing them
HUP0201033A3 (en) Glucagon antagonists/inverse agonists, process for their preparation and their use
IL152700A0 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinc receptor antagonists
IL149600A0 (en) Novel methods and compositions involving opioids and antagonists thereof
IL155634A0 (en) 3-arylindole derivatives and their use as cb2 receptor agonists
AU2002223501A1 (en) Glucagon antagonists/inverse agonists
SI1170288T1 (en) Diphenylureum derivatives and their use as alpha2/5-HT2c antagonists
HK1054391A1 (zh) 毒蕈碱拮抗劑
IL173521A0 (en) Substituted 2 - carbonylamino - 6 piperidinaminopyidines and substituted 1 - carbonylamino - 3 - piperidinaminobenzenes as 5 - th1f agonists
HK1076276A1 (en) 1-Amin-alkylcyclohexanes as 5-ht3 and neuronal nicotinicreceptor antagonists
AU2002223500A1 (en) Glucagon antagonists/inverse agonists
AU4274401A (en) Diphenylalkylamine derivatives useful as opioid delta receptor agonists
IL154343A0 (en) Phenoxybenzylamine derivatives as selective serotonin re-uptake inhibitors
IL152701A0 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
ZA200100978B (en) Muscarinic agonists and antagonists.
EP1453503A4 (en) EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS
AU2002212888A1 (en) Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4)
HUP0303513A3 (en) Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonists and antagonists, their use and pharmaceutical compositions containing them
HUP0301384A2 (en) Urotensin-ii agonists and antagonists
EP1324763A4 (en) AGONISTS AND ANTAGONISTS OF STAT3 AND THERAPEUTIC APPLICATIONS THEREOF
AU2002224772A1 (en) Morphinoid derivatives as delta-opioid agonists and antagonists